HRTX News Alert Heron Therapeutics Inc. (HRTX) 9.75 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Heron Therapeutics Inc. (HRTX) 9.75 $HRTX

5 Stocks Under $10 Setting Up to Trade Higher: Covisint and More
at The Street - Thu Dec 11, 11:46AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
HRTX: 9.75 (+0.02), IO: 2.80 (+0.05), NXTD: 2.46 (-0.09), COVS: 2.73 (+0.08), SZMK: 6.12 (-0.07)

RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST

INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)

Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 02, 7:01AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 2:10 p.m. ET in New York City.
HRTX: 9.75 (+0.02)

Heron Therapeutics beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 9:07AM CST
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $19.2 million in its third quarter.
HRTX: 9.75 (+0.02)

Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV
Business Wire - Thu Nov 06, 7:10AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeutics' lead investigational product candidate, SUSTOL(R) (granisetron injection, extended release), is an extended release 5-HT3 receptor antagonist being developed for the prevention of both acute- and delayed-onset CINV.
HRTX: 9.75 (+0.02)

Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Thu Nov 06, 7:02AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 9.75 (+0.02)

Heron Therapeutics hires Esme C. Smith as VP
M2 - Tue Aug 26, 6:55AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) revealed on Monday the appointment of Esme C. Smith as its vice president, general counsel and secretary.
HRTX: 9.75 (+0.02)

Heron Therapeutics Appoints Esme C. Smith as Vice President, General Counsel and Secretary
Business Wire - Mon Aug 25, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esme C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron's Chief Executive Officer.
HRTX: 9.75 (+0.02)

Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Mon Aug 04, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 9.75 (+0.02)

4 Stocks Under $10 Making Big Moves
at The Street - Wed Jul 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HRTX: 9.75 (+0.02), ACI: 1.78 (+0.01), CNAT: 6.84 (+0.17), IKGH: 1.25 (-0.09)

Heron Therapeutics closes public offering of common stock at USD11.75 per share
M2 - Tue Jul 01, 3:00AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) reported on Monday the completion of its public offering of 4,751,358 shares of common stock at USD11.75 per share.
HRTX: 9.75 (+0.02)

Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
Business Wire - Mon Jun 30, 12:30PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. Gross offering proceeds to Heron Therapeutics, Inc. are approximately $63 million before deducting underwriting discounts and commissions and offering expenses payable by Heron Therapeutics, Inc.
HRTX: 9.75 (+0.02)

Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
HRTX: 9.75 (+0.02), AERI: 29.49 (+1.23), ARIA: 6.81 (+0.15)

Why Heron Therapeutics Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 25, 12:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Heron Therapeutics , a specialty...
HRTX: 9.75 (+0.02)

Heron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jun 25, 8:15AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the pricing of an underwritten offering of 4,500,000 shares of its common stock, offered at a price of $11.75 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. As a component of the offering, in lieu of common stock Heron Therapeutics, Inc. is offering to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about June 30, 2014, subject to customary closing conditions. Jefferies LLC and Leerink Partners LLC are acting as joint book-runners for the offering. JMP Securities LLC, Brean Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.
HRTX: 9.75 (+0.02)

Heron Therapeutics to issue common shares in planned underwritten offering
M2 - Wed Jun 25, 4:52AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) said on Tuesday that it plans to offer and sell shares of its common stock in an underwritten offering.
HRTX: 9.75 (+0.02)

Heron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jun 24, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration. All of the shares in the proposed offering are to be sold by Heron Therapeutics, Inc.
HRTX: 9.75 (+0.02)

Heron Therapeutics (HRTX) in Focus: Stock Gains 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:25AM CDT
Heron Therapeutics (HRTX) was a big mover last session, with shares rising over 7% on the day.
HRTX: 9.75 (+0.02), AERI: 29.49 (+1.23), ARIA: 6.81 (+0.15)

Heron Therapeutics Set to Join Russell 3000 Index
Business Wire - Fri Jun 20, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, announced today that it is set to join the broad-market Russell 3000 Index, as well as the Russell Global and Russell Micro-Cap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on www.russell.com/indexes.
HRTX: 9.75 (+0.02)

Heron Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Thu Jun 12, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 3:00 p.m. ET in New York City.
HRTX: 9.75 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 85

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 0

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 88

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 57

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 97

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 95

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading

Top 5 Most Recently Viewed Articles

Apirone's Transformative Year: Innovations and Achievements

Updated Category News Views 120

Apirone's Transformative Year: Innovations and Achievements As we reflect on the recent progress made by Apirone, a leading cryptocurrency services provider, it is clear that 2025 marked a groundbreaking year in the company’s evolution. With a steadfast commitment to fostering innovation and enhancing user engagement, Apirone has undertaken a series of pivotal...

Continue Reading
Green Rain Energy Enhances Capital Structure with Share Swap

Updated Category News Views 170

Green Rain Energy Takes Strategic Steps to Strengthen Capital Structure Green Rain Energy Holdings Inc. (OTCID: GREH) has made an announcement that reflects its commitment to enhancing shareholder value and addressing market dynamics. The Chief Executive Officer, Alfredo Papadakis, plans to cancel 310 million common shares held through a holding company. This bold move...

Continue Reading
Piper Sandler's Positive View on Webster Financial's Potential

Updated Category News Views 92

Positive Insights from Piper Sandler on Webster Financial Piper Sandler has reaffirmed its Overweight rating on Webster Financial Corporation (NYSE: WBS), setting a steadfast price target of $54.00. This rating reflects confidence in the bank's potential for recovery and growth, despite recent challenges faced by the company. Current Performance Analysis Despite a...

Continue Reading
City Furniture's Grand Opening Sparks Growth in Tampa Region

Updated Category News Views 158

City Furniture Celebrates Exciting Grand Opening CITY Furniture, a leading home furnishings retailer, has celebrated the successful grand opening of its expansive 120,000-square-foot showroom in Sarasota. This event not only marks a significant milestone in the company's growth but also embodies its commitment to transforming the home shopping experience in the Tampa...

Continue Reading
Celebrating Scott Alexander Rose as a Pinnacle Achiever in 2024

Updated Category News Views 238

Scott Alexander Rose Recognized as a Pinnacle Achiever 2024 Scott Alexander Rose has been prominently featured and acknowledged as a Pinnacle Achiever 2024 for his exemplary contributions to education and philanthropy. His dedication reflects a lifetime of service and commitment to making a meaningful impact. A Commitment to Education and Excellence Dr. Rose's academic...

Continue Reading